IRDM: Options Sentiment Flips as Earnings Loom

Iridium Communications heads into its October 23 print with the options market making a sharp about-turn, the most notable one-day shift in positioning seen all year.

Yesterday's previous article noted a call-heavy lean in options, with the put/call ratio running well below its 20-day average. That has reversed dramatically. The PCR jumped to 0.7616 on October 19, more than four standard deviations above its 20-day mean of 0.61. That reading is the highest in the past 52 weeks. In one session, options traders moved from their most bullish stance in weeks to their most defensive stance of the year. The abruptness of the shift is striking: through mid-October the PCR barely moved from its 0.60 anchor, then accelerated sharply into the final trading session before the earnings window.

Short interest, meanwhile, holds where the prior article left it. Around 3.35 million shares remain short, equal to 3.19% of free float, more than double the level from two weeks ago. The borrow market remains entirely unstressed. Availability is at 4,639% of outstanding short interest, shares are freely available, and cost to borrow has eased further to 0.64%. There is no squeeze pressure here. The short position looks deliberate rather than forced, and the loose lending conditions mean it can be maintained or extended cheaply into the print.

The debate around the company itself is genuinely two-sided. Bulls point to Iridium's position as the only truly global low-earth-orbit communications and positioning network, with direct-to-device service and new IoT silicon potentially adding a growth layer that rides on a fixed-cost constellation. EPS momentum factor scores rank in the 92nd and 98th percentiles over 30 and 90 days respectively, suggesting the earnings revision trend has been strongly positive. Bears counter that the revenue picture remains constrained, IoT net subscriber additions have been modest, and cheaper launch economics are eroding the barriers that historically protected the franchise. The stock trades at roughly 28x earnings, with an EV/EBIT multiple that ranks in just the 13th percentile on value. The mean analyst price target of $42.50 is fractionally below the current price of $44.18, leaving little upside in consensus.

One structural overhang sits in the background. Baralonco Limited, which filed a Schedule 13D, holds a 9.44% activist stake, down marginally from 9.53% at its prior filing in August. An agreed takeover by Rocket Lab Corporation is the reason ORTEX forecasts an 84% probability of IRDM's deletion from the Russell 1000, with an estimated $215 million of index-tracker selling to follow. Those dates and flows are estimated and contingent on deal completion. As with all Schedule 13D/G positions, stakes are as last disclosed and a holder dropping below the 5% threshold may not file again.

Thursday's print will test whether the late-breaking surge in put demand was well-placed caution or an overreaction to a stock that has already retraced 6% on the week.